WiseGuyReports.com adds “Myocardial Infarction - Pipeline Review, H1 2016” new report to its research database. The report Spread across 358 pages with tables and figures.
The report “Myocardial Infarction - Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.
Complete Report Details Available at https://www.wiseguyreports.com/reports/myocardial-infarction-pipeline-review-h1-2016-infarction-pipeline-review-h1-2016 .
Companies mentioned in this report are:
Amarantus Bioscience Holdings, Inc., Angion Biomedica Corp., Asterias Biotherapeutics, Inc., AstraZeneca Plc, Athersys, Inc., Bayer AG, Bharat Biotech International Limited, BioCardia, Inc., Biscayne Pharmaceuticals, Inc., Capricor Therapeutics, Inc., CellProthera, Celyad SA, Compugen Ltd., CSL Limited, Cynata Therapeutics Limited, FibroGen, Inc., Hemostemix Ltd, Human Stem Cells Institute, HUYA Bioscience International, LLC, Immune Pharmaceuticals Inc., Juventas Therapeutics, Inc., Laboratoires Pierre Fabre SA, Lee's Pharmaceutical Holdings Limited, LegoChem Biosciences, Inc, LG Life Science LTD., Medestea Research & Production S.p.A., Mesoblast Limited, miRagen Therapeutics, Inc., Moderna Therapeutics, Inc., MorphoSys AG, NeuroVive Pharmaceutical AB, New World Laboratories, Inc., Novartis AG, Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Polyphor Ltd., Primary Peptides, Inc., Quantum Genomics SA, Quark Pharmaceuticals, Inc., Recardio GmbH, Serodus ASA, Silver Creek Pharmaceuticals, Inc., Stealth BioTherapeutics Inc., Stemedica Cell Technologies, Inc., Stempeutics Research Private Limited, TaiGen Biotechnology Co., Ltd., Targazyme, Inc., The International Biotechnology Center (IBC) Generium, TiGenix NV, Vicore Pharma AB, XBiotech USA, Inc., Yuyu Pharma, Inc., Zydus Cadila Healthcare Limited.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/myocardial-infarction-pipeline-review-h1-2016-infarction-pipeline-review-h1-2016 .
- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
P: +44 208 133 9349
M: +1 646 845 9349